Abstract
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).
| Original language | English |
|---|---|
| Pages (from-to) | 67-72 |
| Number of pages | 6 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 140 |
| DOIs | |
| Publication status | Published - Aug 1 2019 |
Fingerprint
Keywords
- BRCA1
- BRCA2
- Genetic testing
- Germline mutations
- Ovarian cancer
- PARP inhibitors
- Somatic mutations
ASJC Scopus subject areas
- Hematology
- Oncology
- Geriatrics and Gerontology
Cite this
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. / Gori, Stefania; Barberis, Massimo; Bella, Maria Angela; Buttitta, Fiamma; Capoluongo, Ettore; Carrera, Paola; Colombo, Nicoletta; Cortesi, Laura; Genuardi, Maurizio; Gion, Massimo; Guarneri, Valentina; Incorvaia, Lorena; La Verde, Nicla; Lorusso, Domenica; Marchetti, Antonio; Marchetti, Paolo; Normanno, Nicola; Pasini, Barbara; Pensabene, Matilde; Pignata, Sandro; Radice, Paolo; Ricevuto, Enrico; Sapino, Anna; Tagliaferri, Pierosandro; Tassone, Pierfrancesco; Trevisiol, Chiara; Truini, Mauro; Varesco, Liliana; Russo, Antonio.
In: Critical Reviews in Oncology/Hematology, Vol. 140, 01.08.2019, p. 67-72.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives
AU - Gori, Stefania
AU - Barberis, Massimo
AU - Bella, Maria Angela
AU - Buttitta, Fiamma
AU - Capoluongo, Ettore
AU - Carrera, Paola
AU - Colombo, Nicoletta
AU - Cortesi, Laura
AU - Genuardi, Maurizio
AU - Gion, Massimo
AU - Guarneri, Valentina
AU - Incorvaia, Lorena
AU - La Verde, Nicla
AU - Lorusso, Domenica
AU - Marchetti, Antonio
AU - Marchetti, Paolo
AU - Normanno, Nicola
AU - Pasini, Barbara
AU - Pensabene, Matilde
AU - Pignata, Sandro
AU - Radice, Paolo
AU - Ricevuto, Enrico
AU - Sapino, Anna
AU - Tagliaferri, Pierosandro
AU - Tassone, Pierfrancesco
AU - Trevisiol, Chiara
AU - Truini, Mauro
AU - Varesco, Liliana
AU - Russo, Antonio
PY - 2019/8/1
Y1 - 2019/8/1
N2 - The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).
AB - The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).
KW - BRCA1
KW - BRCA2
KW - Genetic testing
KW - Germline mutations
KW - Ovarian cancer
KW - PARP inhibitors
KW - Somatic mutations
UR - http://www.scopus.com/inward/record.url?scp=85066629041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066629041&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2019.05.012
DO - 10.1016/j.critrevonc.2019.05.012
M3 - Review article
VL - 140
SP - 67
EP - 72
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -